Artiva Biotherapeutics financials
$7.03−0.28%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | -$26.9M | -$24.4M | -$21.9M | -$22.9M | -$22.8M | -$22.2M | -$18.3M | -$18.3M |
| Net income | -$25.0M | -$23.5M | -$20.8M | -$21.5M | -$21.3M | -$20.3M | -$16.1M | -$17.5M |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.63 | $-0.95 | $-0.85 | $-0.88 | $-0.87 | $-0.83 | $-0.66 | $-0.92 |
| EBITDA | -$26.2M | -$23.8M | -$21.3M | -$22.2M | -$22.2M | -$21.5M | -$17.7M | -$17.7M |
| Operating cash flow | -$20.4M | -$20.9M | -$14.7M | -$19.2M | -$23.0M | -$19.8M | -$14.7M | -$11.6M |
| Free cash flow | -$20.8M | -$21.2M | -$15.1M | -$19.8M | -$24.0M | -$20.4M | -$14.7M | -$11.7M |
| Diluted shares | 39.4M | 24.7M | 24.6M | 24.5M | 24.4M | 24.3M | 24.5M | 18.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $301.5M | $21.0M | $26.7M | $25.5M | $28.5M | $30.4M |
| Short-term investments | $47.9M | $65.8M | $81.3M | $97.5M | $113.9M | $135.6M |
| Total debt | $0.00 | $11.0K | $44.0K | $75.0K | $106.0K | $137.0K |
| Total assets | $368.6M | $106.0M | $130.9M | $148.9M | $169.4M | $191.3M |
| Total liabilities | $21.1M | $18.1M | $21.0M | $19.6M | $20.4M | $22.5M |
| Shareholders' equity | $347.5M | $87.8M | $110.0M | $129.2M | $149.0M | $168.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology